Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afri

Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global Biologics Contract Manufacturing Market is experiencing remarkable growth, with revenues reaching approximately US$ 19.9 billion in 2024. It is projected to reach a market valuation of US$ 40 billion by the end of 2031, according to a recent study by Fairfield Market Research.

Key Market Insights:
• Comprehensive Biopharmaceutical Services: Biologics contract manufacturing involves offering end-to-end services, from medication development to manufacturing, to businesses in the biopharmaceutical sector.
• Growing Biopharmaceutical Pipeline: The industry is witnessing an emphasis on next-generation biotherapeutics, and the extensive biologics pipeline supports expectations of robust growth.
• Clinical Success of Biologics: Over 1,500 biomolecules are undergoing clinical trials, showing a success rate more than twice that of small-molecule products.
• Outsourcing Biopharmaceutical Manufacturing: Biopharmaceutical contract development and manufacturing services are experiencing double-digit growth due to the limited capacity of biopharmaceutical developers and the need for outsourcing.
• Integration and Technological Advancements: Leading Contract Development and Manufacturing Organizations (CDMOs) are expanding integrated capabilities, adopting technological advancements, and focusing on accelerated development and speed to market.
• Single-Use Bioreactor Technology: The rising adoption of single-use (disposable) bioreactor technology for its flexibility and cost-effectiveness is expected to drive market growth.

Market Growth Drivers:

""Growth of Novel Biologic and Biosimilar Manufacturing"" - The biopharmaceutical CMO market is expected to witness consolidation as participants seek inorganic growth strategies to offer integrated solutions. Scientific advancements in biopharmaceuticals are creating opportunities for technologically advanced CDMOs.

Factors Impacting Market Growth:

""Changing Regulatory Dynamics"" - Global regulatory policies, cGMP, and inspection regimes tightening, as well as supply chain security concerns in emerging countries, impact the cost of final products.

Booming U.S. Market:

Strong biologics pipelines, high corporate venture capital investments in biotechnology R&D, and the establishment of important manufacturers and research institutions with specialized programs for CMOs are driving growth in the U.S. market.

Lucrative German Market:

The demand for biopharmaceutical contract manufacturing in Germany is increasing due to more research and clinical trials in biopharmaceuticals, leading to outsourcing research activities to lower costs.

Emerging Chinese Market:

Pharma and biopharma companies are capitalizing on growth opportunities and collaborating with local organizations, contributing to the growth of the biopharmaceutical contract manufacturing market in China.

Competitive Landscape:

Key players are focusing on service enhancements, expanding into developing regions, and strengthening their market presence through expansion, service launches, agreements, partnerships, and online services.

Key Companies Profiled:
• BioXcellence (Boehringer Ingelheim)
• Lonza Group AG
• Samsung Biologics
• Fujifilm Diosynth Biotechnologies
• AbbVie CM (AbbVie Inc.)
• WuXi Biologics (Cayman) Inc.
• AGC Biologics
• Patheon N.V. (Thermo Fisher Scientific Inc.)
• Emergent BioSolutions Inc.
• Ajinomoto Bio-Pharma
• Avid Bioservices, Inc.
• KBI Biopharma
• Rentschler Biotechnologie GmbH
• Merck KGaA
• Catalent Inc.
• Therapure Biopharma Inc.
• Novasep
• Abzena plc.
• ProBioGen AG

Market Segmentation

Product:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Insulin
• Interferons
• Growth Factors
• Others

Platform:
• Mammalian
• Microbial

Therapeutic Area:
• Oncology
• Autoimmune Disease
• Metabolic Disease
• Ophthalmology
• Cardiovascular Disease
• Infectious Disease
• Neurology
• Respiratory Disorder
• Others

Application:
• Commercial
• Clinical

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Biologics Contract Manufacturing Demand Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2018 – 2023
3.1. Global Biologics Contract Manufacturing Demand Market Production Output, by Region, Value (US$ Bn) and Volume (KL), 2018 – 2023
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2018 – 2023
4.1. Global Average Price Analysis, by Product, US$ Per Unit, 2018 – 2023
4.2. Prominent Factor Affecting Protective Sunglasses Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit
5. Global Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
5.1. Global Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Monoclonal Antibodies
5.1.1.2. Recombinant Proteins
5.1.1.3. Vaccines
5.1.1.4. Insulin
5.1.1.5. Interferons
5.1.1.6. Growth Factors
5.1.1.7. Others
5.2. Global Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Mammalian
5.2.1.2. Microbial
5.3. Global Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Oncology
5.3.1.2. Autoimmune Disease
5.3.1.3. Metabolic Disease
5.3.1.4. Opthalmology
5.3.1.5. Cardiovascular Disease
5.3.1.6. Infectious Disease
5.3.1.7. Neurology
5.3.1.8. Respiratory Disorder
5.3.1.9. Others
5.4. Global Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Commercial
5.4.1.2. Clinical
5.5. Global Biologics Contract Manufacturing Demand Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2018 – 2031
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
6.1. North America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Monoclonal Antibodies
6.1.1.2. Recombinant Proteins
6.1.1.3. Vaccines
6.1.1.4. Insulin
6.1.1.5. Interferons
6.1.1.6. Growth Factors
6.1.1.7. Others
6.2. North America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Mammalian
6.2.1.2. Microbial
6.3. North America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Oncology
6.3.1.2. Autoimmune Disease
6.3.1.3. Metabolic Disease
6.3.1.4. Opthalmology
6.3.1.5. Cardiovascular Disease
6.3.1.6. Infectious Disease
6.3.1.7. Neurology
6.3.1.8. Respiratory Disorder
6.3.1.9. Others
6.4. North America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. Commercial
6.4.1.2. Clinical
6.5. North America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1. Key Highlights
6.5.1.1. U.S. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.2. U.S. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.3. U.S. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.4. U.S. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.5. Canada Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.6. Canada Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.7. Canada Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.1.8. Canada Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
7.1. Europe Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Monoclonal Antibodies
7.1.1.2. Recombinant Proteins
7.1.1.3. Vaccines
7.1.1.4. Insulin
7.1.1.5. Interferons
7.1.1.6. Growth Factors
7.1.1.7. Others
7.2. Europe Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Mammalian
7.2.1.2. Microbial
7.3. Europe Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Oncology
7.3.1.2. Autoimmune Disease
7.3.1.3. Metabolic Disease
7.3.1.4. Opthalmology
7.3.1.5. Cardiovascular Disease
7.3.1.6. Infectious Disease
7.3.1.7. Neurology
7.3.1.8. Respiratory Disorder
7.3.1.9. Others
7.4. Europe Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Commercial
7.4.1.2. Clinical
7.5. Europe Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1. Key Highlights
7.5.1.1. Germany Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.2. Germany Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.3. Germany Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.4. Germany Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.5. U.K. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.6. U.K. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.7. U.K. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.8. U.K. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.9. France Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.10. France Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.11. France Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.12. France Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.13. Italy Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.14. Italy Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.15. Italy Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.16. Italy Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.17. Turkey Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.18. Turkey Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.19. Turkey Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.20. Turkey Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.21. Russia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.22. Russia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.23. Russia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.24. Russia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.25. Rest of Europe Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.26. Rest of Europe Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.27. Rest of Europe Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.1.28. Rest of Europe Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
8.1. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Monoclonal Antibodies
8.1.1.2. Recombinant Proteins
8.1.1.3. Vaccines
8.1.1.4. Insulin
8.1.1.5. Interferons
8.1.1.6. Growth Factors
8.1.1.7. Others
8.2. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Mammalian
8.2.1.2. Microbial
8.3. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Oncology
8.3.1.2. Autoimmune Disease
8.3.1.3. Metabolic Disease
8.3.1.4. Opthalmology
8.3.1.5. Cardiovascular Disease
8.3.1.6. Infectious Disease
8.3.1.7. Neurology
8.3.1.8. Respiratory Disorder
8.3.1.9. Others
8.4. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. Commercial
8.4.1.2. Clinical
8.5. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1. Key Highlights
8.5.1.1. China Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.2. China Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.3. China Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.4. China Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.5. Japan Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.6. Japan Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.7. Japan Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.8. Japan Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.9. South Korea Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.10. South Korea Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.11. South Korea Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.12. South Korea Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.13. India Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.14. India Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.15. India Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.16. India Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.17. Southeast Asia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.18. Southeast Asia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.19. Southeast Asia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.20. Southeast Asia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
9.1. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.1.1. Key Highlights
9.1.1.1. Monoclonal Antibodies
9.1.1.2. Recombinant Proteins
9.1.1.3. Vaccines
9.1.1.4. Insulin
9.1.1.5. Interferons
9.1.1.6. Growth Factors
9.1.1.7. Others
9.2. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.2.1.1. Mammalian
9.2.1.2. Microbial
9.3. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.3.1. Key Highlights
9.3.1.1. Oncology
9.3.1.2. Autoimmune Disease
9.3.1.3. Metabolic Disease
9.3.1.4. Opthalmology
9.3.1.5. Cardiovascular Disease
9.3.1.6. Infectious Disease
9.3.1.7. Neurology
9.3.1.8. Respiratory Disorder
9.3.1.9. Others
9.4. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.4.1. Key Highlights
9.4.1.1. Commercial
9.4.1.2. Clinical
9.5. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1. Key Highlights
9.5.1.1. Brazil Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.2. Brazil Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.3. Brazil Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.4. Brazil Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.5. Mexico Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.6. Mexico Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.7. Mexico Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.8. Mexico Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.9. Argentina Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.10. Argentina Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.11. Argentina Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.12. Argentina Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.13. Rest of Latin America Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.14. Rest of Latin America Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.15. Rest of Latin America Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.1.16. Rest of Latin America Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, 2018 – 2031
10.1. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.1.1. Key Highlights
10.1.1.1. Monoclonal Antibodies
10.1.1.2. Recombinant Proteins
10.1.1.3. Vaccines
10.1.1.4. Insulin
10.1.1.5. Interferons
10.1.1.6. Growth Factors
10.1.1.7. Others
10.2. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.2.1. Key Highlights
10.2.1.1. Mammalian
10.2.1.2. Microbial
10.3. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.3.1. Key Highlights
10.3.1.1. Oncology
10.3.1.2. Autoimmune Disease
10.3.1.3. Metabolic Disease
10.3.1.4. Opthalmology
10.3.1.5. Cardiovascular Disease
10.3.1.6. Infectious Disease
10.3.1.7. Neurology
10.3.1.8. Respiratory Disorder
10.3.1.9. Others
10.4. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.4.1. Key Highlights
10.4.1.1. Commercial
10.4.1.2. Clinical
10.5. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1. Key Highlights
10.5.1.1. GCC Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.2. GCC Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.3. GCC Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.4. GCC Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.5. South Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.6. South Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.7. South Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.8. South Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.9. Egypt Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.10. Egypt Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.11. Egypt Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.12. Egypt Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.13. Nigeria Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.14. Nigeria Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.15. Nigeria Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.16. Nigeria Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2018 – 2031
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. Artery Type vs Indication Heatmap
11.2. Manufacturer vs Indication Heatmap
11.3. Company Market Share Analysis, 2023
11.4. Competitive Dashboard
11.5. Company Profiles
11.5.1. Samsung Biologics
11.5.1.1. Company Overview
11.5.1.2. Product Portfolio
11.5.1.3. Financial Overview
11.5.1.4. Business Strategies and Development
11.5.2. BioXcellence (Boehringer Ingelheim)
11.5.2.1. Company Overview
11.5.2.2. Product Portfolio
11.5.2.3. Financial Overview
11.5.2.4. Business Strategies and Development
11.5.3. Lonza Group AG
11.5.3.1. Company Overview
11.5.3.2. Product Portfolio
11.5.3.3. Financial Overview
11.5.3.4. Business Strategies and Development
11.5.4. Fujifilm Diosynth Biotechnologies
11.5.4.1. Company Overview
11.5.4.2. Product Portfolio
11.5.4.3. Financial Overview
11.5.4.4. Business Strategies and Development
11.5.5. AbbVie CM (AbbVie Inc.)
11.5.5.1. Company Overview
11.5.5.2. Product Portfolio
11.5.5.3. Financial Overview
11.5.5.4. Business Strategies and Development
11.5.6. WuXi Biologics (Cayman) Inc.
11.5.6.1. Company Overview
11.5.6.2. Product Portfolio
11.5.6.3. Financial Overview
11.5.6.4. Business Strategies and Development
11.5.7. AGC Biologics
11.5.7.1. Company Overview
11.5.7.2. Product Portfolio
11.5.7.3. Financial Overview
11.5.7.4. Business Strategies and Development
11.5.8. Patheon N.V. (Thermo Fisher Scientific Inc.)
11.5.8.1. Company Overview
11.5.8.2. Product Portfolio
11.5.8.3. Financial Overview
11.5.8.4. Business Strategies and Development
11.5.9. Emergent BioSolutions Inc.
11.5.9.1. Company Overview
11.5.9.2. Product Portfolio
11.5.9.3. Financial Overview
11.5.9.4. Business Strategies and Development
11.5.10. Ajinomoto Bio-Pharma
11.5.10.1. Company Overview
11.5.10.2. Product Portfolio
11.5.10.3. Financial Overview
11.5.10.4. Business Strategies and Development
11.5.11. Avid Bioservices, Inc.
11.5.11.1. Company Overview
11.5.11.2. Product Portfolio
11.5.11.3. Financial Overview
11.5.11.4. Business Strategies and Development
11.5.12. KBI Biopharma
11.5.12.1. Company Overview
11.5.12.2. Product Portfolio
11.5.12.3. Financial Overview
11.5.12.4. Business Strategies and Development
11.5.13. Rentschler Biotechnologie GmbH
11.5.13.1. Company Overview
11.5.13.2. Product Portfolio
11.5.13.3. Financial Overview
11.5.13.4. Business Strategies and Development
11.5.14. Merck KGaA
11.5.14.1. Company Overview
11.5.14.2. Product Portfolio
11.5.14.3. Financial Overview
11.5.14.4. Business Strategies and Development
11.5.15. Catalent Inc.
11.5.15.1. Company Overview
11.5.15.2. Product Portfolio
11.5.15.3. Financial Overview
11.5.15.4. Business Strategies and Development
11.5.16. Therapure Biopharma Inc.
11.5.16.1. Company Overview
11.5.16.2. Product Portfolio
11.5.16.3. Financial Overview
11.5.16.4. Business Strategies and Development
11.5.17. Novasep
11.5.17.1. Company Overview
11.5.17.2. Product Portfolio
11.5.17.3. Financial Overview
11.5.17.4. Business Strategies and Development
11.5.18. Abzena plc.
11.5.18.1. Company Overview
11.5.18.2. Product Portfolio
11.5.18.3. Financial Overview
11.5.18.4. Business Strategies and Development
11.5.19. ProBioGen AG
11.5.19.1. Company Overview
11.5.19.2. Product Portfolio
11.5.19.3. Financial Overview
11.5.19.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings